Exclusion criteria

1. Patients in whom the preferred treatment is CABG

2. Patients with left main coronary artery disease requiring revascularization

3. Patients with a recent (less than 1 week) STEMI or Non-STEMI

4. Prior CABG

5. Contra-indication to dual antiplatelet therapy

6. LVEF < 30%

7. Severe LV hypertrophy (defined as a septal wall thickness at echocardiography of

more than 13 mm)

8. Planned need for concomitant valvular or aortic surgery

9. Extremely tortuous or calcified coronary arteries precluding FFR measurements

10. A life expectancy of less than 2 years

11. Age under 21 4

12. Pregnancy or intention to become pregnant during the course of the trial

13. Refusal or inability to sign an informed consent. Mental condition (psychiatric or

organ cerebral disease) rendering the subject unable to understand the nature,

scope, and possible consequences of the trial or mental retardation or language

barrier such that the patient is unable to give informed consent

14. Potential for non-compliance towards the requirements in the trial protocol (especially

the medical treatment) or follow-up visits

15. Participation or planned participation in another cardiovascular clinical trial before two

year follow-up is completed